Positive Final OS Results of Ph 3 JUPITER-02 Trial of Toripalimab as Treatment for Recurrent or mNPC announced February 22, 2023
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible And Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer February 22, 2023
THIO + Atezolizumab or Pembrolizumab demonstrated Significantly Greater Tumor Inhibition February 22, 2023
Final Topline Data from Successful European Ph 1 monotherapy Trial of Annamycin in R/R AML patients announced February 22, 2023
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma February 22, 2023
Opdivo® + CABOMETYX® shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC February 22, 2023
Updated Data Demonstrating Improved Outcomes from Niraparib + Abiraterone + Prednisone in 1L BRCA+ve metastatic CRPC announced February 22, 2023
Positive TALZENNA® and XTANDI® Combination Data from Ph 3 TALAPRO-2 Study Announced February 22, 2023
Adjuvant Opdivo Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk MIBC After 3 Yrs in CheckMate -274 Trial February 22, 2023
Final Results of Key Secondary OS Endpoint From Phase 3 PROpel Trial presented, OS endpoint not met February 22, 2023
KEYTRUDA + Chemo Significantly Improved OS vs chemo Alone in With HER2-Neg Gastric or GEJ Adenocarcinoma Patients Regardless of PD-L1 Expression February 22, 2023
Clinical Responses from the Ph 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer highlighted February 22, 2023
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% vs SoC in Earlier Lines of Therapy for R/R Multiple Myeloma in Ph 3 KarMMa-3 Study February 22, 2023
42-Patient Interim Data, with 90% ORR in R/R Multiple Myeloma at NXC-201 Therapeutic Dose from Ph 1 Expansion Trial presented February 22, 2023
Tecartus® CAR T-Cell Therapy Demonstrates OS Benefit In 3-Year Follow-Up Of Pivotal ZUMA-3 Trial In R/R B-Cell Acute Lymphoblastic Leukemia February 22, 2023
2023 EBMT-EHA: Encouraging initial safety and efficacy data for point-of-care manufactured GLPG5201 CAR-T in rrCLL presented February 22, 2023
NRG-GY018 Study Demonstrates Significantly Improved PFS Outcomes for Women with Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy February 8, 2023
KEYTRUDA + Chemo Met Primary Endpoint of PFS as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma February 8, 2023
TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of CRR in R/R CLL Patients February 1, 2023
Ph 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) meets Primary Endpoint in Patients with R/R Multiple Myeloma February 1, 2023
ASCO GI: OS Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory mCRC presented February 1, 2023
Pivotal Data for Futibatinib in Previously Treated Patients With Metastatic Intrahepatic Cholangiocarcinoma published in the NEJM February 1, 2023